Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.47 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.47 |
| ▸ | ACP3 | P15309 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2300013 | 0.89 | TDP1 (0.55) | TDP1MTNR1AMCL1GRM2GRM3 | |
| SCHEMBL2314388 | 0.84 | MEN1 (0.66) | TDP1MTNR1AMCL1MEN1KMT2A | |
| SCHEMBL1284856 | 0.84 | MTNR1A (0.62) | TDP1MTNR1AMCL1MEN1KMT2A | |
| SCHEMBL29653519 | 0.80 | KMT2A (0.74) | TDP1MTNR1AMEN1KMT2ACYP1A2 | |
| SCHEMBL276470 | 0.80 | KMT2A (0.74) | TDP1MTNR1AMEN1KMT2ACYP1A2 | |
| SCHEMBL10616431 | 0.80 | TDP1 (0.56) | TDP1MTNR1AMCL1MEN1KMT2A | |
| SCHEMBL30900805 | 0.79 | TDP1 (0.61) | TDP1MTNR1AMCL1MEN1KMT2A | |
| SCHEMBL22129565 | 0.79 | TDP1 (0.61) | TDP1MTNR1AMCL1MEN1KMT2A | |
| SCHEMBL5830948 | 0.79 | GPR84 (0.59) | TDP1MTNR1AMCL1ACP3GPR84 | |
| SCHEMBL9800436 | 0.79 | CYP1A2 (0.58) | TDP1MTNR1AMCL1ACP3GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949552-B2 | Remedial agent for anxiety neurosis or depression and piperazine derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| US-20030186992-A1 | Remedial agent for anxiety neurosis or depression and piperazine derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1295608-A1 | REMEDIAL AGENT FOR ANXIETY NEUROSIS OR DEPRESSION AND PIPERAZINE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186992-A1 | Remedial agent for anxiety neurosis or depression and piperazine derivative | CNR1, HTR4, TPH1 | TDP1 3332/4885MTNR1A 16/4885MCL1 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.